Heron Therapeutics (NASDAQ:HRTX) Stock Price Up 8.9%

Heron Therapeutics, Inc. (NASDAQ:HRTX) rose 8.9% during trading on Wednesday . The stock traded as high as $3.33 and last traded at $3.32. Approximately 1,123,353 shares were traded during mid-day trading, a decline of 57% from the average daily volume of 2,607,393 shares. The stock had previously closed at $3.05.

Wall Street Analyst Weigh In

HRTX has been the subject of several research reports. Capital One Financial began coverage on Heron Therapeutics in a research note on Tuesday, April 23rd. They issued an “overweight” rating and a $6.00 target price for the company. Rodman & Renshaw began coverage on Heron Therapeutics in a research report on Thursday, June 13th. They issued a “buy” rating and a $7.00 price target on the stock. Finally, Needham & Company LLC restated a “buy” rating and issued a $5.00 price target on shares of Heron Therapeutics in a research report on Thursday, May 16th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $6.00.

Heron Therapeutics Stock Up 9.2 %

The company has a fifty day simple moving average of $3.14 and a two-hundred day simple moving average of $2.67. The stock has a market capitalization of $501.66 million, a P/E ratio of -5.31 and a beta of 1.81.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.06. The business had revenue of $34.67 million for the quarter, compared to the consensus estimate of $32.50 million. As a group, equities analysts forecast that Heron Therapeutics, Inc. will post -0.1 earnings per share for the current year.

Institutional Trading of Heron Therapeutics

Institutional investors have recently modified their holdings of the company. Headlands Technologies LLC bought a new stake in shares of Heron Therapeutics in the first quarter valued at about $30,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Heron Therapeutics in the first quarter valued at about $32,000. Victory Capital Management Inc. lifted its holdings in shares of Heron Therapeutics by 30.2% in the fourth quarter. Victory Capital Management Inc. now owns 19,929 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 4,617 shares in the last quarter. ACT Advisors LLC. bought a new stake in shares of Heron Therapeutics in the fourth quarter valued at about $38,000. Finally, Diversified Trust Co bought a new stake in shares of Heron Therapeutics in the first quarter valued at about $66,000. 80.01% of the stock is currently owned by institutional investors.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.